trending Market Intelligence /marketintelligence/en/news-insights/trending/Uk7yRr9J-gCMijxXu0AwNw2 content esgSubNav
In This List

Ladenburg Thalmann downgrades Fidus Investment to 'neutral' from 'buy'

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Podcast

Street Talk | Episode 99 - Higher rates punish bond portfolios, weigh on bank M&A

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Ladenburg Thalmann downgrades Fidus Investment to 'neutral' from 'buy'

Ladenburg Thalmann analyst Mickey Schleien downgraded Fidus Investment Corp. to "neutral" from "buy" and removed its price target.

The business development company reported adjusted second-quarter net investment income per share of 34 cents, which missed the consensus estimate of 38 cents and the analyst's estimate of 37 cents. Oaktree Medical's placement on full non-accrual resulted in an 11% quarter-over-quarter decrease in investment income, according to Schleien.

Oaktree Medical is under probe for allegedly improperly billing Medicare and making excessive opioid prescriptions, according to the report.

Merits include relatively low balance sheet leverage, dividend coverage and acceptable net investment income yield, Schleien said. The analyst also pointed out concerns such as investment concentration, credit watch investment levels and payment-in-kind income, and the lack of an incentive fee cap mechanism.